Skip to main navigation
Header | Myriad Genetics
Myriad Logo
  • Investor Relations
  • Financial Reporting
    • Filings and Reports
      • SEC Filings
      • Quarterly & Annual Reports
      • Sustainability
    • Disclosures
      • GAAP to Non-GAAP Reconciliation
    • Resources
      • Investor FAQs
      • Email Alerts Subscription
  • Newsroom
  • About Myriad
    • Corporate information
      • Corporate Governance
      • Executive Team
      • Myriad Milestones
    • Latest events
      • Events & Presentations
      • Investor Day
  • Contact Us
NASDAQ:
MYGN
$4.75
3.49%
DAY HIGH

$4.83

YEAR HIGH

$8.74

DAY LOW

$4.44

YEAR LOW

$3.76

04/02/2026
    NASDAQ:
    MYGN
    $4.75
    3.49%
  • Investor Relations
  • Financial Reporting
    • Filings and Reports
      • SEC Filings
      • Quarterly & Annual Reports
      • Sustainability
    • Disclosures
      • GAAP to Non-GAAP Reconciliation
    • Resources
      • Investor FAQs
      • Email Alerts Subscription
  • Newsroom
  • About Myriad
    • Corporate information
      • Corporate Governance
      • Executive Team
      • Myriad Milestones
    • Latest events
      • Events & Presentations
      • Investor Day
  • Contact Us

Investor Relations

  • News Releases
    • All
    • Financial News
    • Corporate News
    • Product News
    • Pipeline News

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

  • Read more about Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

  • Read more about Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

  • Read more about Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

  • Read more about Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

  • Read more about Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

  • Read more about Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the F

  • Read more about Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the F

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

  • Read more about Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Myriad Genetics Announces Pricing of Upsized Offering of Common Stock

  • Read more about Myriad Genetics Announces Pricing of Upsized Offering of Common Stock

Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock

  • Read more about Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock

Pagination

  • Previous page ‹‹
  • Page 3
  • Next page ››
Subscribe to Financial

Investor Relations Contact

Matt Scalo
801.584.3532
matt.scalo@myriad.com

Stock Quote

Stock Quote

Day High
Year High
Day Low
Year Low
Volume

Minimum 15 minutes delayed. Source: LSEG

Shareholder Tools

  • Email Alerts Subscription
  • Print
  • Share
  • RSS
  • Payers
  • Overview
  • Investors
  • Events + Presentations
  • News
  • Press Releases
  • Myriad Genetics Blog
  • Careers
  • Joining the Team
Myriad Genetics Logo
  • Terms of Use
  • Myriad Genetics, Inc. Privacy Policy
  • Language Assistance
  • Cookie Preferences
© 2022 Myriad Genetics, Inc.